---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-303862"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:52:56.402280+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharma amends inducement plan, increases share reserve to 900,000

## Summary
- Amended 2025 Inducement Plan on Nov 24, 2025, increasing share reserve from 775,000 to 900,000 common shares.
- Plan is exclusively for inducing new employees or rehires after a bona fide interruption of employment.
- No shareholder approval sought under Nasdaq Listing Rule 5635(c)(4); plan meets inducement grant rules.
- Awards include nonstatutory stock options, SARs, restricted stock units, restricted stock, and performance awards.

## SEC filing metadata
- accession: 0001193125-25-303862
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000119312525303862/0001193125-25-303862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000119312525303862/xene-20251124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-303862
- JSON: https://secwatch.observer/filing/0001193125-25-303862.json
- Plain text: https://secwatch.observer/filing/0001193125-25-303862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.